GSK-811936/001 (Hib-MenC-TT-001)

Phase 2, open, randomized, controlled study to demonstrate the non-inferiority of the meningococcal serogroup C immune response and the superiority of the Hib immune response of GSK Biologicals’ Haemophilus influenzae type b-meningococcal C-TT conjugate vaccine administered with Infanrix™ penta versus Meningitec™ administered with Infanrix™
Meningococcal Vaccine
811936/001 (Hib-MenC-TT-001)
Infections, Meningococcal
Phase 2
An annotated case report form is not available for this study. A blank case report form will be provided. A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
June 2015